SPL Shares Starpharma Holdings Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Drug-delivery platform and improving sector momentum provide optionality across licensing and healthcare products.
Future value: $1.22 (+156.84%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Shares gained strongly during recent biotech-sector momentum.
- ▾Below 50-day MA (-36.43%)
- ▸~157% upside to price target
Is SPL a buy right now?
Trend: SPL is trading below the 50-day average (-37.16%), RSI 62 — neutral momentum, with a 3-month return of -38.00%.
Valuation & quality: Starpharma Holdings Limited trades on forward P/E 103.3, price-to-book 14.09; fundamentals show net margin -58.9%, return on equity -45.6%, revenue growth -55.8% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$1.22 (+162.4% vs the last close; range A$1.19 – A$1.25), consensus rating “strong buy”.
Our screen: ACCUMULATE (score 1) — Drug-delivery platform and improving sector momentum provide optionality across licensing and healthcare products.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +6.50% | +49.00% | -4.10% | +0.00% | +7.10% | -4.00% | +20.80% | -46.00% |
Fundamentals
Analyst price target
Technical signals
About Starpharma Holdings Limited
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · 50 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.